Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

Right Versus Left Colon Cancer: Resectable and Metastatic Disease

(2018) Michele Ghidini et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial

(2018) Yungan Tao et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bispecific antibodies for cancer therapy: A review

(2018) Anuradha Krishnamurthy et al.   PHARMACOLOGY & THERAPEUTICS

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager

(2018) Anna Wing et al.   Cancer Immunology Research

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

(2018) Lillian Sun et al.   Journal for ImmunoTherapy of Cancer

Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer

(2017) Amanda Rosewell Shaw et al.   MOLECULAR THERAPY

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy

(2017) Riikka Havunen et al.   Molecular Therapy-Oncolytics

Prospects for combined use of oncolytic viruses and CAR T-cells

(2017) Adam Ajina et al.   Journal for ImmunoTherapy of Cancer

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor

(2015) S. Tahtinen et al.   Cancer Immunology Research

An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites

(2015) Xinping Fu et al.   Oncotarget

Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors

(2014) N. Nishio et al.   CANCER RESEARCH

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis Through Virus-induced Immunomodulation

(2013) Shashi Gujar et al.   MOLECULAR THERAPY

T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy

(2013) Feng Yu et al.   MOLECULAR THERAPY

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

(2013) M. V. Maus et al.   Cancer Immunology Research

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer

(2011) Shashi A Gujar et al.   MOLECULAR THERAPY